3
Indication details
- Control Arm
- Single arm (Phase II)
- FDA Therapeutic Indication
- For the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options
- Tumour Type
-
Brain Tumours
- Tumour Sub-type
- Glioma (high grade)
- Tumour Stage
- Unresectable or metastatic
- Tumour Sub-Group
- BRAF V600E
- Trial Name
- ROAR
- NCT Number
- NCT02034110
- Trial Phase
- Phase II
Primary Outcome(s)
- Primary Outcome(s)
- Investigator-assessed ORR
- Evaluated Outcome
- ORR
- Form(s)
- Form 3
Outcome Data
- PFS Control
- 3.8 months
- ORR
- 33%
- DoR
- 36.9 months
Score (after adjustments)
- Preliminary non-curative score
-
3
- Non-curative score
-
3
- Comment
-
FDA accelerated approval June 2022
Scorecard details
- Scorecard ID
- 346
- Scorecard version
- 1
- Issue date
- 07.09.2022
Legend
Information about symbols, abbrevations and color codes
Red = negative
Green = positive
Grey = neutral
?
Grey + ? = neutral with pending data
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
QoL adjustments
Red = negative / deterioration
Green = positive / improvement
Other adjustments*
Red = negative / deterioration
Green = positive / improvement
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include:
- Long-term plateau in the survival curve
- Long-term plateau in the PFS curve
- Early stopping or crossover
- Only improved PFS mature data shows no OS advantage and no improved Qol.